page 6/7
|
||
|
>Medicine |
GINKGO BILOBA in Medicine |
|
The
first mentioned use of Ginkgo biloba appears in China. Ginkgo leaf is
first mentioned in Lan Mao's Dian Nan Ben Cao, published in 1436
during the Ming dynasty. Lan Mao notes external use to treat skin and
head sores as well as freckles. Internal use of the leaves is first
noted in Liu Wen-Tai's Ben Cao Pin Hui Jing Yao , an imperial
commissioned work recorded in 1505. Liu Wen Tai notes use of the leaves
in the treatment of diarrhea. The leaves of ginkgo are known in Chinese
medicine as bai-guo-ye. Recent clinical reports in modern China suggest
that the leaves lower serum cholesterol levels and have some clinical
value in angina pectoris.
In Traditional Chinese pharmacopeia the seeds (with fleshy rind removed) are considered more important than the leaves. The nut, called Pak Ko, is recommended to expel phlegm, stop wheezing and coughing, urinary incontinence and spermatorrhea. The raw seed is said to help bladder ailments, menorrhea, uterine fluxes, and cardiovascular ailments. The powdered leaf is inhaled for ear, nose, and throat disorders like bronchitis and chronic rhinitis. Locally applied boiled leaves are used for chilblains.. The seeds are used as an astringent for the lung, to stop asthma and enuresis.
Ginkgo leaves are a Chinese herb that has been used much more in the West than in its homeland. Over five hundred scientific studies on the chemistry, pharmacology and clinical effects of gingko leaves have been conducted by European researchers over the last 20 to 30 years. The majority of studies on ginkgo leaf extract have involved a product produced by a German/French consortium, referred to in the scientific literature as EGb761.
More
informations on Ginkgo biloba Extract Page
More informations on Ginkgo biloba Extract Page
The extract utilized in medicine is standardized in a multi-step procedure designed to concentrate the desired active principles from the plant. These extracts contain approximately 24% flavone glycosides (primarily composed of quercetin, kaempferol, and isorhamnetin) and 6% terpene lactones (2.8-3.4% ginkgolides A, B, and C, and 2.6-3.2% bilobalide). Other constituents include proanthocyanadins, glucose, rhamnose, organic acids, D-glucaric acid and ginkgolic acid (at most 5 ppm ginkgolic acids). Biochemical studies have concentrated on the flavonoids: much of the curative properties of the ginkgo tree are due to the activities of these flavonoids. The complex extract itself, rather than a single isolated component, is believed to be responsible for Ginkgo's biological activity.
|
Ginkgo leaf extracts have been shown to have a wide range of biological activities. The most well-known use is the ability to improve short term memory. Other important effects include a protective effect on the blood-brain barrier and an anti-radical (antioxidant) effect. The leaf extracts has also been shown to increase vasodilation and peripheral blood flow rate in capillary vessels and end-arteries in various circulatory disorders. Ginkgo leaf helps to maintain integrity and permeability of cell walls by inhibiting lipid peroxidation of membranes. Other studies have shown vascular-tone regulating effects, and help in modulating cerebral energy metabolism. |
|
Ginkgo standardized extracts have been widely used in Europe for a wide variety of clinical conditions
1)
Alzheimer's Disease / age-related dementia: Ginkgo extracts appear to be capable of stabilizing
and, in some cases, improving the cognitive performance of patients with
schizophrenia.
Based on a quantitative analysis of the literature there is a small but
significant effect of 3 to 6 month treatment with 120 to 240 mg of Gbe on objective measures of cognitive function in
Alzheimer's Disease ( Oken, Oregon Health Sciences University, 1998 ). The last
publication ( Le Bars, Memory Centers of America, New York, Jan 2002 ) indicated
that " a
treatment effect favorable to EGb could be observed with respect to
cognitive performance and social functioning regardless of the stage of dementia, whether mild or moderately severe.
However, the relative changes from baseline measured at endpoint depended
heavily on the severity at baseline. Improvement was observed in the group
of patients with very mild to mild cognitive impairment, while in more
severe dementia, the mean EGb effect should be considered more in terms of
stabilization or slowing down of worsening, as compared to the greater
deterioration observed with placebo". Further research in the area will need to determine if
there are functional improvements and to determine the best dosage.
Additional research will be needed to define which ingredients in the ginkgo
extract are producing its effect in individuals with AD. A recent study makes clear that EGb treatment may enhance
the effectiveness of antipsychotic drugs and reduce their extrapyramidal side
effects ( Zhang, Yale University School of Medicine, 2001 ).
2) Cardiovascular Disease: Treatment with Ginkgo biloba extract lowers fibrinogen levels and decreases plasma viscosity ( EGb can limit oxidative stress )
3) Cerebral vascular insufficiency and impaired cerebral performance: Administration of EGb has been shown to improve a variety of conditions associated with cognitive functions, particularly for memory loss, attention, alertness, vigilance, reaction times and depressive mood. A recent australian study indicates significant improvements in speed of information processing working memory and executive processing attributable to the EGb ( Stough C, Swinburne University of Technology, Melbourne, 2001 ).
Other therapeutic applications include:
1) Congestive symptoms of premenstrual syndrome: Ginkgo extract was effective for the treatment of the congestive (particularly breast symptoms) and neuropsychological symptoms of PMS.
2) Intermittent Claudication: A recent meta-analysis ( Pittler, University of Exeter, 2000 ) found a significant difference in the increase in pain-free walking distance in favor of Ginkgo biloba (weighted mean difference: 34 meters ). In studies using similar methodological features (ergometer speed: 3 km/h, inclination: 12%) this difference was 33 meters in favor of Ginkgo biloba.
3) Vertigo / Equilibrium Disorder / Prevention of altitude sickness.
4) Tinnitus (ringing in the ear). An overview ( Holstein, Karlsruhe, 2001 ) of results of 19 clinical trials shows a statistically significant superiority of treatment with the Gbe 761 as compared with placebo or reference drugs applied of periods of 1 to 3 months. " Therapeutic success was not directly correlated with either the genesis or the duration of tinnitus. However, investigations of prognostic factors revealed that short-standing disorders have a better prognosis, so that better results can be expected from early-onset treatment."
5) Liver Fibrosis: Ginkgo biloba was shown to be effective in arresting the development of liver fibrosis associated with chronic hepatitis B.
6) Macular degeneration: In spite of the small population sample, a statistically significant improvement in long distance visual acuity was observed in patients with macular degeneration.
| Clostre F |
Ginkgo biloba extract. State of knowledge in
the dawn of the year 2000 |
| Drew S |
Effectiveness of Ginkgo biloba in treating tinnitus: double blind, placebo controlled trial. BMJ 2001 Jan 13;322(7278):73 FREE full text article at bmj.com |
| Holstein N. |
Ginkgo special extract EGb 761 in tinnitus therapy. An overview of results of completed clinical trials Fortschr Med 2001 Jan 11;118(4):157-64 |
| Le Bars PL |
Influence of the Severity of Cognitive Impairment on the
Effect of the Ginkgo biloba Extract EGb 761((R)) in Alzheimer's Disease. |
| McKenna DJ |
Efficacy, safety, and use of ginkgo biloba in clinical and
preclinical applications. |
| Moulton PL |
The effect of Ginkgo biloba on memory in healthy male volunteers. Physiol Behav. 2001 Jul;73(4):659-65. |
| Oken BS |
The efficacy of Ginkgo biloba on cognitive function in
Alzheimer disease. |
| Pittler MH |
Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials. Am J Med 2000 Mar;108(4):276-81 |
| Stough C |
Neuropsychological changes after 30-day Ginkgo biloba administration in healthy participants. Int J Neuropsychopharmacol. 2001 Jun;4(2):131-4. |
| Yoshikawa T |
Ginkgo biloba leaf extract: review of biological actions and clinical applications. Antioxid Redox Signal. 1999 Winter;1(4):469-80. Review. |
| Zhang XY |
A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J Clin Psychiatry. 2001 Nov;62(11):878-83. |
Current interest in Ginkgo biloba relates to potential medical applications of the plant extracts. The major active component of GBE was considered, until 1993, to be a flavonoid complex that removed free radicals in the peripheral and/or cerebral vascular systems, and also as a inhibitor of lipid peroxidation. More recent evidence suggests that the ginkgolides may be more important bioactive ingredients in the leaf extract, as they are platelet activating factor (PAF) antagonists. An increase in PAF occurs in asthma, graft rejection and in immune disorders that induce toxic shock. Ginkgolide B and related diterpenes inhibit the binding of PAF to receptors on the cell surface of some human leukocytes.
There is no doubt that ginkgo leaf extracts are of clinical benefit for a number of clinical conditions. More research will be published in the next few years that will further confirm ginkgo's utility.
I am not affiliated with any of the products presented on this page.
|
More informations about Ginkgo tree.... |
||
| 101 Ginkgo biloba | Ginkgo Extract | Where to see ? |
| Ginkgo in France | My Photos Gallery | Ginkgo design |